JP2018503649A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018503649A5 JP2018503649A5 JP2017539596A JP2017539596A JP2018503649A5 JP 2018503649 A5 JP2018503649 A5 JP 2018503649A5 JP 2017539596 A JP2017539596 A JP 2017539596A JP 2017539596 A JP2017539596 A JP 2017539596A JP 2018503649 A5 JP2018503649 A5 JP 2018503649A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline
- composition
- compound
- pyrrole
- chlorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 70
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 66
- 150000001875 compounds Chemical class 0.000 claims description 56
- HLXHAXFWWGYXQW-UHFFFAOYSA-N 2-amino-2-(3-chlorophenyl)ethanol Chemical compound OCC(N)C1=CC=CC(Cl)=C1 HLXHAXFWWGYXQW-UHFFFAOYSA-N 0.000 claims description 36
- 241000124008 Mammalia Species 0.000 claims description 36
- -1 5-Chloro-2-isopropylaminopyridin-4-yl Chemical group 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 24
- 239000012458 free base Substances 0.000 claims description 22
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 claims description 16
- 238000001157 Fourier transform infrared spectrum Methods 0.000 claims description 16
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 14
- 241000282412 Homo Species 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 12
- 241000288906 Primates Species 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 12
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 12
- 244000144972 livestock Species 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 238000001228 spectrum Methods 0.000 claims description 8
- NCBIFXNQFURYON-UHFFFAOYSA-N 4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1h-pyrrole-2-carboxylic acid Chemical compound C1=NC(NC(C)C)=CC(C=2C=C(NC=2)C(O)=O)=C1Cl NCBIFXNQFURYON-UHFFFAOYSA-N 0.000 claims description 6
- KSERXGMCDHOLSS-UHFFFAOYSA-N n-[1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1h-pyrrole-2-carboxamide Chemical compound C1=NC(NC(C)C)=CC(C=2C=C(NC=2)C(=O)NC(CO)C=2C=C(Cl)C=CC=2)=C1Cl KSERXGMCDHOLSS-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 28
- TXSJHWLRGWAOSQ-UHFFFAOYSA-N N-[1-(3-chlorophenyl)-2-hydroxyethyl]-1-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]pyrrole-2-carboxamide Chemical compound CC(C)NC1=NC=C(Cl)C(=C1)N1C=CC=C1C(=O)NC(CO)C1=CC(Cl)=CC=C1 TXSJHWLRGWAOSQ-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 description 40
- KSERXGMCDHOLSS-LJQANCHMSA-N CC(C)Nc(nc1)cc(-c2c[nH]c(C(N[C@H](CO)c3cccc(Cl)c3)=O)c2)c1Cl Chemical compound CC(C)Nc(nc1)cc(-c2c[nH]c(C(N[C@H](CO)c3cccc(Cl)c3)=O)c2)c1Cl KSERXGMCDHOLSS-LJQANCHMSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110449P | 2015-01-30 | 2015-01-30 | |
| US62/110,449 | 2015-01-30 | ||
| PCT/US2016/015829 WO2016123574A1 (en) | 2015-01-30 | 2016-01-29 | Crystalline forms of c21h22ci2n4o2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020063198A Division JP2020100674A (ja) | 2015-01-30 | 2020-03-31 | Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018503649A JP2018503649A (ja) | 2018-02-08 |
| JP2018503649A5 true JP2018503649A5 (enExample) | 2019-02-14 |
| JP7258460B2 JP7258460B2 (ja) | 2023-04-17 |
Family
ID=56544441
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539596A Active JP7258460B2 (ja) | 2015-01-30 | 2016-01-29 | Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態 |
| JP2020063198A Pending JP2020100674A (ja) | 2015-01-30 | 2020-03-31 | Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態 |
| JP2021195403A Pending JP2022033866A (ja) | 2015-01-30 | 2021-12-01 | Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態 |
| JP2023081553A Withdrawn JP2023096080A (ja) | 2015-01-30 | 2023-05-17 | Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態 |
| JP2025050047A Pending JP2025089464A (ja) | 2015-01-30 | 2025-03-25 | Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020063198A Pending JP2020100674A (ja) | 2015-01-30 | 2020-03-31 | Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態 |
| JP2021195403A Pending JP2022033866A (ja) | 2015-01-30 | 2021-12-01 | Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態 |
| JP2023081553A Withdrawn JP2023096080A (ja) | 2015-01-30 | 2023-05-17 | Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態 |
| JP2025050047A Pending JP2025089464A (ja) | 2015-01-30 | 2025-03-25 | Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態 |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US9676746B2 (enExample) |
| EP (2) | EP4477222A3 (enExample) |
| JP (5) | JP7258460B2 (enExample) |
| CN (2) | CN116854662A (enExample) |
| AU (5) | AU2016211246B2 (enExample) |
| CA (2) | CA3218488A1 (enExample) |
| ES (1) | ES3009552T3 (enExample) |
| HK (1) | HK1244274A1 (enExample) |
| MX (1) | MX382289B (enExample) |
| NZ (2) | NZ734041A (enExample) |
| SG (2) | SG10202101979TA (enExample) |
| WO (1) | WO2016123574A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| MX382289B (es) | 2015-01-30 | 2025-03-13 | Biomed Valley Discoveries Inc | Formas cristalinas de c21h22cl2n4o2. |
| SI3378479T1 (sl) * | 2016-01-27 | 2020-10-30 | Jiangsu Hengrui Medicine Co., Ltd. | Postopek za pripravo farmacevtskega sestavka, ki obsega derivat kinolina ali njegovo sol |
| WO2021020841A1 (en) * | 2019-07-29 | 2021-02-04 | Standigm Inc. | Composition for preventing or treating metabolic liver disease |
| WO2021102279A1 (en) * | 2019-11-20 | 2021-05-27 | University Of Kentucky Research Foundation | Anti-cancer compositions and methods |
| WO2023169480A1 (zh) * | 2022-03-08 | 2023-09-14 | 甘李药业股份有限公司 | 氘代化合物，及其制备方法和应用 |
| CN119212985A (zh) * | 2022-03-24 | 2024-12-27 | 生物医学谷探索股份有限公司 | Erk的吡咯抑制剂的氘代类似物、其合成及其中间体 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599331A (en) | 1984-12-24 | 1986-07-08 | Syntex (U.S.A.) Inc. | Etianic acids as antiangiogenics |
| ES2041245T3 (es) | 1985-10-23 | 1993-11-16 | The Upjohn Company | Esteroides angioestaticos. |
| US4771042A (en) | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
| WO1990015816A1 (en) | 1989-06-16 | 1990-12-27 | The Upjohn Company | Suramin type compounds and angiostatic steroids to inhibit angiogenesis |
| CA2425841C (en) | 1991-11-22 | 2006-01-10 | Alcon Laboratories, Inc. | Angiostatic steroids |
| EP1200422A2 (en) | 2000-02-05 | 2002-05-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US7304061B2 (en) | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
| DK3305776T3 (da) | 2004-05-14 | 2019-12-09 | Vertex Pharma | Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser |
| US7582623B2 (en) | 2004-05-20 | 2009-09-01 | The Regents Of The University Of California | Photoactive metal nitrosyls for blood pressure regulation and cancer therapy |
| CN103951583B (zh) | 2006-12-06 | 2016-01-06 | 科内图斯医药公司 | 一种抑制剂的结晶形式 |
| EP2897615A4 (en) * | 2012-09-18 | 2016-04-27 | Auspex Pharmaceuticals Inc | PHARMACOKINETIC FORMULATIONS OF DEUTERATED BENZOCHINOL INHIBITORS OF THE VESICLE MONOAMINE TRANSPORTER 2 |
| US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| MX382289B (es) | 2015-01-30 | 2025-03-13 | Biomed Valley Discoveries Inc | Formas cristalinas de c21h22cl2n4o2. |
-
2016
- 2016-01-29 MX MX2017009696A patent/MX382289B/es unknown
- 2016-01-29 WO PCT/US2016/015829 patent/WO2016123574A1/en not_active Ceased
- 2016-01-29 AU AU2016211246A patent/AU2016211246B2/en active Active
- 2016-01-29 CN CN202310821608.XA patent/CN116854662A/zh active Pending
- 2016-01-29 SG SG10202101979TA patent/SG10202101979TA/en unknown
- 2016-01-29 CA CA3218488A patent/CA3218488A1/en active Pending
- 2016-01-29 NZ NZ734041A patent/NZ734041A/en unknown
- 2016-01-29 JP JP2017539596A patent/JP7258460B2/ja active Active
- 2016-01-29 US US15/011,377 patent/US9676746B2/en active Active
- 2016-01-29 NZ NZ772411A patent/NZ772411A/en unknown
- 2016-01-29 SG SG11201705924RA patent/SG11201705924RA/en unknown
- 2016-01-29 EP EP24203987.3A patent/EP4477222A3/en active Pending
- 2016-01-29 CN CN201680013774.5A patent/CN107406413A/zh active Pending
- 2016-01-29 HK HK18103713.0A patent/HK1244274A1/zh unknown
- 2016-01-29 EP EP16744240.9A patent/EP3250562B1/en active Active
- 2016-01-29 CA CA2975048A patent/CA2975048C/en active Active
- 2016-01-29 ES ES16744240T patent/ES3009552T3/es active Active
-
2017
- 2017-05-17 US US15/598,181 patent/US10183927B2/en active Active
-
2018
- 2018-12-20 US US16/227,820 patent/US10738027B2/en active Active
-
2020
- 2020-03-31 JP JP2020063198A patent/JP2020100674A/ja active Pending
- 2020-07-07 US US16/922,365 patent/US11390600B2/en active Active
- 2020-10-20 AU AU2020257041A patent/AU2020257041C1/en active Active
-
2021
- 2021-12-01 JP JP2021195403A patent/JP2022033866A/ja active Pending
-
2022
- 2022-06-16 US US17/842,632 patent/US12187698B2/en active Active
- 2022-09-05 AU AU2022228084A patent/AU2022228084B2/en active Active
-
2023
- 2023-05-17 JP JP2023081553A patent/JP2023096080A/ja not_active Withdrawn
- 2023-10-25 AU AU2023254937A patent/AU2023254937B2/en active Active
-
2024
- 2024-11-26 US US18/960,604 patent/US20250084059A1/en active Pending
-
2025
- 2025-03-25 JP JP2025050047A patent/JP2025089464A/ja active Pending
- 2025-11-10 AU AU2025263912A patent/AU2025263912A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018503649A5 (enExample) | ||
| JP2015512942A5 (enExample) | ||
| JP2021530565A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| JP2013522232A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2014516360A5 (enExample) | ||
| BRPI0813625A2 (pt) | Imidazo-[1,2b]-piridozinas 2,3,7-substituídos para tratamento de doenças mediadas por alzk4 ou alk5 | |
| JP2016522266A5 (enExample) | ||
| JP2014526469A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2015501799A5 (enExample) | ||
| JP2012533570A5 (enExample) | ||
| JP2014507455A5 (enExample) | ||
| JP2014510149A5 (enExample) | ||
| JP2010514806A5 (enExample) | ||
| PH12016501651A1 (en) | Triazine compound and use thereof for medical purposes | |
| RU2015103065A (ru) | Кристаллическая форма i дималеата ингибитора тирозинкиназы и способ ее получения | |
| JP2018534288A5 (enExample) | ||
| JP2014534269A5 (enExample) | ||
| CA2447765A1 (en) | 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors | |
| JP2009511519A5 (enExample) | ||
| RU2017134709A (ru) | П-толуолсульфонат для ингибитора мек-киназы и его кристаллическая форма, и способ его получения | |
| CA2647346A1 (en) | Malate salts, and polymorphs of (3s,5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid | |
| EP4477222A3 (en) | Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt |